List view / Grid view
Scientists identify thousands of novel enhancers linked to neuronal differentiation and neuropsychiatric disorders, offering new pathways for drug discovery and potential therapeutic targets.
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
Huntsman Cancer Institute researchers have identified a gene variant in Andean populations that could predict blood cancer treatment outcomes and potentially lead to targeted therapies.
A study from the University of Alabama at Birmingham reveals that HIF1α plays a crucial role in enabling T cells to kill tumour cells under low-oxygen conditions, providing a potential solution to resistance in immune checkpoint blockade (ICB) therapies.
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
Listen to this episode to discover how microbiomics is being leveraged to translate gut microbiome findings into new therapeutic options.
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
Protein biomarkers in spinal fluid linked to PSP could enable earlier diagnosis and treatment for this neurological disorder.
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
The study’s findings explain the genetic differences in people’s blood pressure, which could lead to personalised medicine approaches.
